{
  "citations": [],
  "guideline": {
    "objCls": "Guideline Annotation",
    "id": "PA166220321",
    "name": "Annotation of CPIC Guideline for esomeprazole, rabeprazole and CYP2C19",
    "alternateDrugAvailable": false,
    "cancerGenome": false,
    "crossReferences": [
      {
        "id": 1451254360,
        "resource": "URL",
        "resourceId": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/",
        "_url": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/",
        "version": 0
      }
    ],
    "descriptiveVideoId": "KgRrti8dIRs",
    "dosingInformation": false,
    "guidelineGenes": [],
    "hasTestingInfo": false,
    "history": [
      {
        "id": 1451243920,
        "date": "2020-08-11T13:55:36.349-07:00",
        "description": "posted",
        "type": "Update",
        "version": 0
      },
      {
        "id": 1451612282,
        "date": "2021-12-09T14:02:57.535-08:00",
        "description": "Added video",
        "type": "Update",
        "version": 0
      }
    ],
    "literature": [
      {"id":15113542,"title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868475","crossReferences":[{"id":1451837569,"resource":"PubMed Central","resourceId":"PMC7868475","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868475"},{"id":1451242280,"resource":"PubMed","resourceId":"32770672","_url":"https://www.ncbi.nlm.nih.gov/pubmed/32770672"},{"id":1451242281,"resource":"DOI","resourceId":"10.1002/cpt.2015","_url":"http://dx.doi.org/10.1002%2Fcpt.2015"}],"objCls":"Literature","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}]}
    ],
    "pediatric": false,
    "recommendation": false,
    "relatedAlleles": [],
    "relatedChemicals": [
      {
        "objCls": "Chemical",
        "id": "PA10075",
        "name": "esomeprazole",
        "version": 15
      },
      {
        "objCls": "Chemical",
        "id": "PA451216",
        "name": "rabeprazole",
        "version": 13
      }
    ],
    "relatedGenes": [
      {
        "objCls": "Gene",
        "id": "PA124",
        "symbol": "CYP2C19",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "version": 7209
      }
    ],
    "source": "CPIC",
    "summaryMarkdown": {
      "id": 1451231900,
      "html": "<p>The CPIC Dosing Guideline for <em>CYP2C19</em> and Proton Pump Inhibitor Dosing states that inconsistent findings regarding the effect of <em>CYP2C19</em> genotype on the pharmacokinetics and therapeutic response to esomeprazole and rabeprazole preclude making recommendations for these proton pump inhibitors.</p>\n",
      "version": 0
    },
    "terms": [],
    "textMarkdown": {
      "id": 1451433681,
      "html": "<p>This annotation is based on the <a rel=\"noopener noreferrer\" href=\"https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/\" target=\"_blank\">CPIC&reg; Guideline for CYP2C19 and Proton Pump Inhibitor Dosing</a>.</p>\n<h3 id=\"august-2020\">August 2020</h3>\n<p><em>Advance online publication August 2020.</em></p>\n<ul>\n<li>\n<p>The <a rel=\"noopener noreferrer\" href=\"https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.2015\" target=\"_blank\">CPIC Guideline for CYP2C19 and Proton Pump Inhibitor Dosing</a> is published in <em>Clinical Pharmacology and Therapeutics</em>.</p>\n</li>\n<li>\n<p>These guidelines are applicable to:</p>\n<ul>\n<li>pediatric patients</li>\n<li>adult patients</li>\n</ul>\n</li>\n<li>\n<p>Excerpts from the 2020 Proton Pump Inhibitor Dosing dosing guideline:</p>\n<ul>\n<li>&quot;There is less evidence linking <em>CYP2C19</em> genotype with variability in plasma concentrations and effectiveness of second-generation PPIs (esomeprazole, rabeprazole, and dexlansoprazole).&quot;</li>\n<li>&quot;The evidence associating <em>CYP2C19</em> genotype with esomeprazole, rabeprazole, and dexlansoprazole plasma concentrations, efficacy, and toxicity was graded as moderate or weak.&quot; (see guideline supplement)</li>\n<li>&quot;Inconsistent findings regarding the effect of <em>CYP2C19</em> genotype on the pharmacokinetics and therapeutic response to esomeprazole and rabeprazole preclude making recommendations for these second-generation PPIs (i.e., CPIC level C; no recommendation).&quot;</li>\n</ul>\n</li>\n<li>\n<p>Download and read:</p>\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/PPI/2020/32770672.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium guideline for <em>CYP2C19</em> and Proton Pump Inhibitors</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://files.cpicpgx.org/data/guideline/publication/PPI/2020/32770672-supplement.pdf\" target=\"_blank\">2020 supplement</a></li>\n</ul>\n</li>\n</ul>\n",
      "version": 0
    },
    "userId": "katrin",
    "version": 3
  }
}